A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Trial details
- Registry ID
- NCT05275673
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CB-228
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerNCT05275673 | Faeth Therapeutics | Phase 2 | Terminated | 2023-01-24Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |